https://pk26124inhibitor.com/y....our-impact-associate
The underyling spectral range of pathology is complex and creates a challenge for targeted molecular treatments. We here tested the hypothesis that leukotrienes are involved in the pathology of DLB and that preventing leukotrienes through Montelukast, a leukotriene receptor antagonist and approved anti-asthmatic medicine, might relieve pathology and restore cognitive functions. Appearance of 5-lipoxygenase, the rate-limiting enzyme for leukotriene production, had been certainly raised in brains with DLB.
Like
Comment
Share
